Chemical Namevenetoclax
Dosage FormTablet (oral; 10 mg, 50 mg, 100 mg)
Drug ClassInhibitors
CompanyAbbVie Inc.
Approval Year2016


  • For chronic lymphocytic leukemia in patients with a specific chromosomal abnormality.
  • In combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Last updated on 12/21/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Venclexta (venetoclax) Prescribing Information 2019AbbVie Inc., North Chicago, IL